Article Link: https://www.pharmavoice.com/news/fda-iovance-til-solid-tumor-cell-therapy/707988/
Part 2: How T Cell Activation Redefines TIL and CAR-T Manufacturing (Boosting Success Rates to 95%) with Chantale Bernatchez
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from...